Provided by Tiger Trade Technology Pte. Ltd.

Myriad Genetics

4.38
+0.09002.10%
Post-market: 5.431.05+23.97%19:59 EST
Volume:2.68M
Turnover:12.22M
Market Cap:408.28M
PE:-1.00
High:4.40
Open:4.27
Low:4.10
Close:4.29
52wk High:15.18
52wk Low:3.76
Shares:93.21M
Float Shares:85.72M
Volume Ratio:2.81
T/O Rate:3.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3589
EPS(LYR):-1.4051
ROE:-72.52%
ROA:-5.67%
PB:1.10
PE(LYR):-3.12

Loading ...

Myriad Genetics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
8 hours ago

Myriad Genetics Shares up 18.72% at $5.19 in Extended Trade Following Results, Outlook

THOMSON REUTERS
·
9 hours ago

Myriad Genetics Q4 adjusted EPS beats estimates

Reuters
·
9 hours ago

Myriad Genetics reports Q4 adjusted EPS 4c, consensus (2c)

TIPRANKS
·
9 hours ago

Myriad Q4 net loss narrows to USD 7.9 million from a year earlier

Reuters
·
10 hours ago

BRIEF-Myriad Genetics Q4 EPS USD -0.08

Reuters
·
10 hours ago

Myriad Genetics Inc: Q1'26 Revenue Expected to Be Between $200 Mln and $203 Mln

THOMSON REUTERS
·
10 hours ago

Myriad Genetics Q4 Gross Margin 70%

THOMSON REUTERS
·
10 hours ago

Myriad Genetics Inc: Reiterate Full Year 2026 Revenue Range

THOMSON REUTERS
·
10 hours ago

Myriad Genetics Inc expected to post a loss of 1 cent a share - Earnings Preview

Reuters
·
Feb 21

Myriad Genetics Publishes Clinical Chemistry Validation of FirstGene Multiple Prenatal Screen

Reuters
·
Feb 19

Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

GlobeNewswire
·
Feb 17

Myriad Genetics management to meet with BTIG

TIPRANKS
·
Feb 04

Myriad Genetics to Launch Precise MRD Test for Breast Cancer in March 2026

Reuters
·
Jan 27

Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data

GlobeNewswire
·
Jan 27

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Myriad Genetics (MYGN)

TIPRANKS
·
Jan 13

BRIEF-Myriad Genetics Announces Select Preliminary Fourth Quarter And Full Year 2025 Financial Results And Introduces Full Year 2026 Financial Guidance

Reuters
·
Jan 12

Myriad Genetics Projects 2025 Revenue Between $822 Million and $824 Million

Reuters
·
Jan 12

Myriad Genetics Inc - Full Year 2025 Revenues Expected Between $822 Mln and $824 Mln

THOMSON REUTERS
·
Jan 12

Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire
·
Jan 06